Assistant professor medicine Karolinska Institute, Stockholm, 1975-1986, associate professor, 1986-1996. Senior assistant physician Serafimer Hospital, 1978-1980. Head internal medicine, department oncology Karolinska Hospital and Institute, 1980-1985, head biotherapy and lymphoma unit, 1985-1996, deputy director, 1986-1996.
Professor experimental oncology and head physician University Uppsala and Academy Hospital, Sweden, 1996-1999. Managing director Cancer Center Karolinska, Karolinska Institute/Hospital, since 1999. Professor oncology Biotherapy, Karolinska Institute, since 1999.
Science advisor Centoccor, Malvern, United States of America, 1988-2000, E. Merck GmbH, Darmstadt, Germany, 1990-1994, Pasteur-Merieux Serum and Vaccines, Lyon, France, 1996-2004, Pharmacia AB, Stockholm, 1992-2000, Cell Research Corporation, Cambridge, Massachusetts, 1994-2000, BioInvent AB, Lund, Sweden, 1995-2005, Glaxo-Wellcome, Ltd., London, 1995-2000, GemVax, Oslo, since 2002, Affibody AB, Stockholm, since 2001, Wilex GmbH, Munich, since 2005, Amgen Europe, Zurich, since 2005. Chairman clinical trial advisory board Oxgiene Inc., Boston, since 1998.
Achievements include characterization of clonal tumor cells in myeloma. Identification of a specific T cell tumor response in myeloma. Development of treatment regimen with a-interferon of multiple myeloma, of a therapeutic concept of monoclonal antibodies and cytokines in colorectal carcinoma, and of a tumor vaccine in colorectal carcinoma based on anti-idiotypic antibodies and cloned antigens.
Analysis, in humans, in combination with General Motors-Cerebrospinal fluid, of induction of a humoral and cellular idiotypic cascade after treatment with monoclonal antibodies.
1975 - 1986
1978 - 1980
1980 - 1985
1996 - 1999
- show more ...